Cryoseal fibrin sealant shows promise in TKA (total knee arthroplasty):
This article was originally published in Clinica
Executive Summary
ThermoGenesis says that an early study has produced evidence to support the use of its CryoSeal autologous fibrin sealant in total knee arthroplasty (TKA). The 21-patient pilot trial showed that total blood loss in TKA was reduced by 50% when using the sealant. The CryoSeal patients also had better cardiovascular stability, a higher range of motion, less pain and better wound healing than the control group. Plans are underway to confirm the results in a larger study. It has been estimated that over 1.3 million TKA procedures are performed annually worldwide, says the Rancho Cordova, California firm. The CryoSeal FS system is CE-marked for sale in Europe.
You may also be interested in...
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.
Partisan Politics Returns To US FDA Congressional Oversight
The US FDA has stood out as an agency that tends to draw broad bipartisan support amid a generally rancorous and divided Congress. A House hearing, however, may be a sign that those days are over.
GLP-1 Coverage Restrictions In Medicare Part D Surge As Demand For Obesity Drugs Grows
A major shift from unfettered coverage to prior authorizations was recorded by MMIT over the past year for the leading GLP-1/GIP agonist diabetes drugs. Public interest in using the drugs off label for weight loss drove the change.